Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. to recover losses incurred by shareholders due to alleged securities fraud between February 21, 2025, and August 28, 2025 [2]. Group 1: Lawsuit Details - The lawsuit alleges that the defendants made false statements and concealed information regarding Telix's progress on prostate cancer therapeutic candidates, the quality of its supply chain, and the overall business prospects, which were materially false and misleading [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to visit the provided link to learn about their rights to seek recovery, with no cost or obligation to participate [4]. Group 3: Law Firm Background - Levi & Korsinsky LLP, the firm handling the lawsuit, has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and undisclosed information regarding the company's prostate cancer therapeutic candidates and supply chain issues [2][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Telix and its executives violated federal securities laws by making false statements and failing to disclose critical information about the company's progress and supply chain quality [5]. Group 2: Impact of Regulatory Actions - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, leading to a more than 13% drop in the price of its American Depositary Shares over two trading sessions [6]. - On August 28, 2025, Telix announced receiving a Complete Response Letter from the U.S. Food and Drug Administration regarding its product TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls package, resulting in a more than 21% decline in share price over two trading sessions [7]. Group 3: Class Action Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members and oversees the litigation [8]. - Any member of the class may move to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors in Telix Pharmaceuticals Ltd. for the period between February 21, 2025, and August 28, 2025, due to alleged misleading statements regarding the company's business and operations [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Telix's defendants made materially false and misleading statements about the progress of prostate cancer therapeutic candidates and the quality of the company's supply chain and partners [5]. - Investors who purchased Telix securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must move the Court by January 9, 2026, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

New York, New York--(Newsfile Corp. - November 14, 2025) - If you suffered a loss on your Telix Pharmaceuticals Ltd. (NASDAQ: TLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/telix-pharmaceuticals-ltd-lawsuit-submission-form?prid=177498&wire=5&utm_campaign=1or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder ...

Core Viewpoint - Telix Pharmaceuticals Limited is facing a securities class action lawsuit following significant stock declines due to a regulatory subpoena and an FDA rejection letter [1] Group 1: Legal Proceedings - The lawsuit, titled Thomas v. Telix Pharmaceuticals Ltd., seeks to represent investors who acquired Telix securities between February 21, 2025, and August 28, 2025 [3] - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [2][8] Group 2: Company Statements and Allegations - The litigation focuses on Telix's statements regarding its prostate cancer therapeutic candidates TLX591 and TLX592, as well as its kidney cancer detection candidate Zircaix [4] - During the class period, Telix claimed significant progress in its therapeutic pipeline and emphasized its global manufacturing capabilities as a competitive advantage [5] - The lawsuit alleges that Telix made false and misleading statements, overstating the progress of its prostate cancer candidates and the quality of its supply chain [5] Group 3: Regulatory Issues - On July 22, 2025, Telix disclosed an SEC investigation into its disclosures related to the development of its prostate cancer therapeutic candidates, which negatively impacted its stock price [6] - On August 28, 2025, Telix received a Complete Response Letter from the FDA for its Zircaix BLA, citing deficiencies in chemistry, manufacturing, and controls, which further affected its stock performance [7]

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Telix Pharmaceuticals Limited (TLX) Shareholders to Inquire About Securities Fraud Class Action. ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit set for January 9, 2026 [1][3]. Group 1: Allegations Against Telix Pharmaceuticals - The complaint alleges that Telix and its executives made false and misleading statements regarding the progress of prostate cancer therapeutic candidates, overstated the quality of the supply chain, and provided materially false information about the company's business and prospects [3]. - Following the announcement of a subpoena from the U.S. Securities and Exchange Commission on July 22, 2025, Telix's American Depositary Shares (ADSs) fell more than 13% over two trading sessions [4]. - On August 28, 2025, Telix disclosed receiving a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its product TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package, leading to a further decline of over 21% in the price of Telix's ADSs [5]. Group 2: Legal Proceedings and Investor Actions - The lead plaintiff in the class action lawsuit will be the investor with the largest financial interest who is typical of class members, and any member of the class can move to serve as lead plaintiff [6]. - Faruqi & Faruqi encourages individuals with information regarding Telix's conduct, including whistleblowers and former employees, to contact the firm [6].

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLXNovember 13, 2025 4:17 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 13, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between Febru ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Telix Pharmaceuticals Ltd. securities for the period between February 21, 2025, and August 28, 2025, due to alleged misleading statements made by the company [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Telix Pharmaceuticals made materially false and misleading statements regarding its progress with prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. - Investors are entitled to compensation without any out-of-pocket fees through a contingency fee arrangement if they purchased Telix securities during the class period [2]. - A lead plaintiff must move the Court by January 9, 2026, to represent other class members in the litigation [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in the field [4].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Telix Pharmaceuticals Limited ("Telix†or the "Company†) (NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclusive (the "Class Period†). Telix investors have until January 9, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS. ...